394 related articles for article (PubMed ID: 29284202)
1. Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.
Tahara M; Muro K; Hasegawa Y; Chung HC; Lin CC; Keam B; Takahashi K; Cheng JD; Bang YJ
Cancer Sci; 2018 Mar; 109(3):771-776. PubMed ID: 29284202
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
[TBL] [Abstract][Full Text] [Related]
3. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
6. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.
Doi T; Piha-Paul SA; Jalal SI; Saraf S; Lunceford J; Koshiji M; Bennouna J
J Clin Oncol; 2018 Jan; 36(1):61-67. PubMed ID: 29116900
[TBL] [Abstract][Full Text] [Related]
7. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
Ott PA; Piha-Paul SA; Munster P; Pishvaian MJ; van Brummelen EMJ; Cohen RB; Gomez-Roca C; Ejadi S; Stein M; Chan E; Simonelli M; Morosky A; Saraf S; Emancipator K; Koshiji M; Bennouna J
Ann Oncol; 2017 May; 28(5):1036-1041. PubMed ID: 28453692
[TBL] [Abstract][Full Text] [Related]
8. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
Sacco AG; Chen R; Worden FP; Wong DJL; Adkins D; Swiecicki P; Chai-Ho W; Oppelt P; Ghosh D; Bykowski J; Molinolo A; Pittman E; Estrada MV; Gold K; Daniels G; Lippman SM; Natsuhara A; Messer K; Cohen EEW
Lancet Oncol; 2021 Jun; 22(6):883-892. PubMed ID: 33989559
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.
Mehra R; Seiwert TY; Gupta S; Weiss J; Gluck I; Eder JP; Burtness B; Tahara M; Keam B; Kang H; Muro K; Geva R; Chung HC; Lin CC; Aurora-Garg D; Ray A; Pathiraja K; Cheng J; Chow LQM; Haddad R
Br J Cancer; 2018 Jul; 119(2):153-159. PubMed ID: 29955135
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.
Yap TA; Nakagawa K; Fujimoto N; Kuribayashi K; Guren TK; Calabrò L; Shapira-Frommer R; Gao B; Kao S; Matos I; Planchard D; Chatterjee A; Jin F; Norwood K; Kindler HL
Lancet Respir Med; 2021 Jun; 9(6):613-621. PubMed ID: 33836153
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Fuchs CS; Doi T; Jang RW; Muro K; Satoh T; Machado M; Sun W; Jalal SI; Shah MA; Metges JP; Garrido M; Golan T; Mandala M; Wainberg ZA; Catenacci DV; Ohtsu A; Shitara K; Geva R; Bleeker J; Ko AH; Ku G; Philip P; Enzinger PC; Bang YJ; Levitan D; Wang J; Rosales M; Dalal RP; Yoon HH
JAMA Oncol; 2018 May; 4(5):e180013. PubMed ID: 29543932
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
Mehnert JM; Bergsland E; O'Neil BH; Santoro A; Schellens JHM; Cohen RB; Doi T; Ott PA; Pishvaian MJ; Puzanov I; Aung KL; Hsu C; Le Tourneau C; Hollebecque A; Élez E; Tamura K; Gould M; Yang P; Stein K; Piha-Paul SA
Cancer; 2020 Jul; 126(13):3021-3030. PubMed ID: 32320048
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
Bauml J; Seiwert TY; Pfister DG; Worden F; Liu SV; Gilbert J; Saba NF; Weiss J; Wirth L; Sukari A; Kang H; Gibson MK; Massarelli E; Powell S; Meister A; Shu X; Cheng JD; Haddad R
J Clin Oncol; 2017 May; 35(14):1542-1549. PubMed ID: 28328302
[TBL] [Abstract][Full Text] [Related]
19. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
Leighl NB; Hellmann MD; Hui R; Carcereny E; Felip E; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Lubiniecki GM; Zhang J; Piperdi B; Garon EB
Lancet Respir Med; 2019 Apr; 7(4):347-357. PubMed ID: 30876831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
